Month: April 2024

Oslo, 26 April 2024 – Adevinta ASA today released its 2023 Annual Report, available here. A printed copy may be obtained free of charge upon written request to: ir@adevinta.com. Reflecting on 2023, Antoine Jouteau, CEO, said: “Over the past year, we have made significant progress on redesigning our operating model, verticalising our organisation in line with our Growing At Scale strategy and successfully completing our portfolio optimisation. We have achieved strong financial and operational performance in 2023 and continued to deliver against our targets, despite the tough macroeconomic environment. Following the divestment of our Hungarian classifieds business, our portfolio is now centred around our core European markets of France, Germany, Spain, Italy and Benelux, complemented by Canada and our joint ventures. We are delivering significant...

Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024. The full Quarterly Statement Q1 2024 can be downloaded here: https://medigene.com/investors-media/reports-presentations/. “During the first quarter of 2024, our focus remained on executing our strategic plan and advancing the development of our unique TCR-T therapies for solid tumors, such as our lead program MDG1015,” said Selwyn Ho, CEO at Medigene. “While our core expertise lies in generating optimal TCRs, we are also exploring ways to broaden their application beyond TCR-T cell therapies.” “The recently announced capital...

Company announcement no. 29 It is hereby announced that Spar Nord has received the permission of the Danish Financial Supervisory Authority to repay bond loans (ISIN DK0030431341) for DKK 150 million and (ISIN DK0030431341) for DKK 350 million, currently both classified as Tier 2 capital. The repayment will take place on 29 May 2024. Please direct any questions regarding this release to Rune Brandt Børglum, Head of Investor Relations, on tel. + 45 9634 4236, or by e-mail at rsn@sparnord.dk. Rune Brandt BørglumHead of Investor RelationsAttachmentNo. 29 – Spar Nord repays Tier 2 capital – UK

        Company announcement no. 28            As stated in company announcement no. 22, it was decided at Spar Nord Bank A/S’ ordinary general meeting on 19 March 2024 to reduce the company’s share capital by DKK 27,645,950 nominal value divided into 2,764,595 shares of DKK 10 through the cancellation of treasury shares. The capital reduction was published via the Danish Business Authority’s IT system on 26 March 2024. The statutory notice period has expired with no claims received. The capital reduction has been finally registered with the Danish Business Authority on 25 April 2024. After the capital reduction, the share capital of Spar Nord Bank A/S amounts to DKK 1,177,020,310 nominal value divided into shares of DKK 10 each. Pursuant to section 32 of the Danish Capital Markets Act, we hereby announce that the company’s...

Brussels – 26 April 2024 – Implementing the Federal Hydrogen Act of 11 July 2023, Federal Energy Minister Tinne Van der Straeten has appointed Fluxys hydrogen, a subsidiary of Fluxys Belgium, as operator for the development and management of a hydrogen transmission grid in Belgium. The appointment as “HNO” – Hydrogen Network Operator – for Belgium is a major step forward in the energy transition. Leveraging Fluxys’ decades of expertise in gas transport, Fluxys hydrogen will develop the necessary infrastructure for transporting hydrogen, an essential component to reach the climate targets. In accordance with the federal hydrogen strategy, Fluxys hydrogen will undertake the development and operation of a hydrogen pipeline network, which will be part of the “European Hydrogen Backbone”. This will enable...

First-quarter EBITDA1 was USD 435 million compared to USD 487 million in first quarter 2023. Net income was USD 16 million (USD 0.07 per share) compared with USD 105 (USD 0.41 per share) a year earlier. First-quarter 2024 highlights:EBITDA1 down 11% from 1Q23 mainly due to lower prices Total deliveries up 12% with European deliveries up 37% from 1Q23 Reduced GHG emission intensity with implementation of key projects Healthy demand growth and limited capacity additions indicate tightening supply-demand balance longer term“This quarter’s results are down from same quarter last year as increased deliveries are offset by lower prices. Meanwhile, I am pleased to see that our efforts to decarbonize is yielding results. This is crucial to future-proof our business and be able to meet growing demand for low-carbon solutions”, said Svein...

Information relative au nombre total de droits de vote et d’actions composant le capital social au 25 avril 2024 Information relating to the total number of voting rights and shares making up the share capitalat 25 April 2024 Articles L 233-8 II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Articles L 233-8 II of the French Commercial Code and 223-16 of the AMF General Regulations Place de cotation : NYSE Euronext-Paris Compartiment : Eurolist BCode ISIN : FR0014003FE9Date d’arrêté des informations   Declaration date Nombre total d’actions composant le capital social   Total number of shares in the share capital   Nombre total de droits de vote     Total number of voting rights25 avril 2024April 25, 2024 97 161 351 Nombre théorique des droits de vote (1)Number...

STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report – January-March 2024. The full report is available on the Company’s website. “2024 has begun strongly with development within the respective portfolio companies proceeding according to plan. The adverse market climate we have previously experienced notwithstanding, our portfolio companies have continued tirelessly to advance the development of tomorrow’s treatments in order that patients can reap the benefits as quickly as possible. We look forward to an increasing tailwind and further progress during the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarterThe portfolio company OssDsign reported positive data from the clinical study TOP FUSION. Top-line results show...

2024 first quarter revenues: +20% Order book at the end of March 2024: +4% Bezons, April 26, 2024 – 8:00am (CET) – RIBER, the global leader for molecular beam epitaxy (MBE) equipment serving the semiconductor industry, is reporting its revenues for the first quarter of 2024. Change in revenuesAt March 31 (€m) 2024 2023 ChangeSystems 2.0 1.9 +6%Services and accessories 2.5 1.8 +35%Total quarterly revenues 4.5 3.7 +20%2024 first-quarter revenues amounted to €4,5m, up +20%. Revenues for MBE systems increased by 6% to €2.0m and included billing for one machine. Revenues for services and accessories rose by 35% to €2.5m. At end-March 2024, the geographical breakdown of the Company’s revenues was as follows: 71% in Europe, 21% in Asia and 8% in North America. Order book developmentsAt March 31 (€m) 2024 2023 ChangeSystems 27.9 26.7 +5%Services...

Progress on ABN AMRO share buyback programme 19 April – 25 April 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 19 April 2024 up to and including 25 April 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.72 for a total amount of €47,170,980. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €452,072,460 representing 90.41% of the overall share buyback programme.ABN AMRO Press Office ABN AMRO...